Biogen Inc.

NASDAQ Global Select
Back to all articles
Bullish +72

Biogen stock trades near its 52-week high on growth bets

Earnings report Financial outlook AI-generated analysis

📈 Biogen stock traded at USD 228, just 0.52 percent below its 52-week high of USD 229.19 on September 24, 2026.

💰 Q2 2026 revenue reached USD 2.74 billion, up 3.4 percent year-over-year and above the USD 2.46 billion consensus estimate.

📊 Adjusted EPS hit USD 3.60 in Q2/2026, beating the USD 2.94 consensus by USD 0.66 despite a 34 percent decline from the prior year.

💊 Core pharmaceutical revenue grew 4 percent to USD 1.8 billion, providing stability against declining legacy multiple sclerosis products.

🚀 The growth portfolio exceeded USD 1 billion and expanded by 24 percent year-over-year in the second quarter.

📅 Management guided fiscal 2026 adjusted EPS between USD 12.00 and USD 13.00 for the upcoming year.

🗓️ The company scheduled its third-quarter earnings release for October 28, 2026, before the market opens.

🏢 Biogen's market capitalization was valued at approximately USD 33.7 billion as of September 24, 2026.

Bullish Signals
  • Biogen stock traded near its 52-week high of USD 229.19, closing at USD 228 on September 24, 2026, reflecting strong investor sentiment.
  • Q2 revenue of USD 2.74 billion exceeded the consensus estimate of USD 2.46 billion by USD 280 million, driven by a 3.4 percent year-over-year increase.
  • Adjusted EPS of USD 3.60 beat the analyst consensus of USD 2.94 by USD 0.66, demonstrating strong profitability despite higher costs.
  • Core pharmaceutical revenue grew 4 percent to USD 1.8 billion, successfully offsetting declines in legacy multiple sclerosis products.
  • The growth portfolio surpassed USD 1 billion in revenue and expanded by 24 percent year-over-year, validating the company's strategic expansion.
Risk Factors
  • Adjusted earnings declined 34 percent year-over-year to USD 3.60 due to significant deal-related costs and increased research spending.
  • The company faces ongoing pressure on established medicines as it transitions away from its legacy multiple sclerosis product portfolio.
Full Analysis
Biogen stock traded near its 52-week high of USD 229.19 on September 24, 2026, closing at USD 228 as investors reacted to strong second-quarter financial results. The company reported Q2 revenue of USD 2.74 billion, representing a 3.4 percent increase year-over-year and significantly beating the consensus estimate of USD 2.46 billion. Financial performance highlighted a strategic shift within Biogen's portfolio, with core pharmaceutical revenue rising 4 percent to USD 1.8 billion while the growth portfolio exceeded USD 1 billion with a 24 percent increase. Although adjusted earnings per share declined 34 percent year-over-year due to deal-related costs and research spending, the company still posted an adjusted EPS of USD 3.60, surpassing analyst expectations by USD 0.66. Management provided fiscal 2026 guidance for adjusted EPS between USD 12.00 and USD 13.00, signaling continued confidence in the business despite the transition away from legacy multiple sclerosis products. The market capitalization stood at approximately USD 33.7 billion as investors weighed these fresh growth signals against the ongoing pressure on established medicines. Biogen scheduled its third-quarter results release for October 28, 2026, before the market opens, which will serve as a key checkpoint for further validation of its revenue and launch strategy. The stock's proximity to its yearly high suggests sustained investor interest in the company's ability to execute its portfolio expansion plans effectively.